Pembrolizumab for melanoma- safety profile and future trends

被引：7
作者：
Daud, Adil [1 ]
Nandoskar, Prachi [1 ]
机构：
[1] UCSF Helen Diller Comprehens Canc Ctr, Melanoma Clin Res, Dept Med Hematol Oncol, 1600 Divisadero St,Box 1297, San Francisco, CA 94115 USA
来源：
EXPERT OPINION ON DRUG SAFETY | 2016年 / 15卷 / 06期
关键词：
Melanoma; pembrolizumab; safety; cancer immunotherapy; PD-1; SOLID TUMORS; PATIENTS PTS; IPILIMUMAB; MK-3475; CHEMOTHERAPY; ASSOCIATION; KEYNOTE-002; THERAPY; CANCER; PEMBRO;
D O I：
10.1080/14740338.2016.1175430
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：727 / 729
页数：3
相关论文
共 14 条
[1]  
Daud A, 2015, P AM SOC CLIN ONCO S, V33, P9005, DOI DOI 10.1200/JC0.2014.57.5027
[2]   Current and Emerging Perspectives on Immunotherapy for Melanoma [J].
Daud, Adil .
SEMINARS IN ONCOLOGY, 2015, 42 (06) :S3-S11
[3]   Nivolumab in melanoma: latest evidence and clinical potential [J].
Johnson, Douglas B. ;
Peng, Chengwei ;
Sosman, Jeffrey A. .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2015, 7 (02) :97-106
[4]   Immunology beats cancer: a blueprint for successful translation [J].
Pardoll, Drew M. .
NATURE IMMUNOLOGY, 2012, 13 (12) :1129-1132
[5]   Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors [J].
Patnaik, Amita ;
Kang, S. Peter ;
Rasco, Drew ;
Papadopoulos, Kyriakos P. ;
Elassaiss-Schaap, Jeroen ;
Beeram, Muralidhar ;
Drengler, Ronald ;
Chen, Cong ;
Smith, Lon ;
Espino, Guillermo ;
Gergich, Kevin ;
Delgado, Liliana ;
Daud, Adil ;
Lindia, Jill A. ;
Li, Xiaoyun Nicole ;
Pierce, Robert H. ;
Yearley, Jennifer H. ;
Wu, Dianna ;
Laterza, Omar ;
Lehnert, Manfred ;
Iannone, Robert ;
Tolcher, Anthony W. .
CLINICAL CANCER RESEARCH, 2015, 21 (19) :4286-4293
[6]   Immune Checkpoint Blockade in Cancer Therapy [J].
Postow, Michael A. ;
Callahan, Margaret K. ;
Wolchok, Jedd D. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1974-U161
[7]   Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL). [J].
Puzanov, Igor ;
Dummer, Reinhard ;
Schachter, Jacob ;
Pavlick, Anna C. ;
Gonzalez, Rene ;
Ascierto, Paolo Antonio ;
Margolin, Kim Allyson ;
Hamid, Omid ;
Agarwala, Sanjiv S. ;
Carlino, Matteo S. ;
Utikal, Jochen ;
Lotem, Michal ;
Ribas, Antoni ;
Mohr, Peter ;
Roach, Charlotte M. ;
Dolled-Filhart, Marisa ;
Li, Xiaoyun Nicole ;
Ebbinghaus, Scot ;
Kang, Soonmo Peter ;
Daud, Adil .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8]   Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial [J].
Ribas, Antoni ;
Puzanov, Igor ;
Dummer, Reinhard ;
Schadendorf, Dirk ;
Hamid, Omid ;
Robert, Caroline ;
Hodi, F. Stephen ;
Schachter, Jacob ;
Pavlick, Anna C. ;
Lewis, Karl D. ;
Cranmer, Lee D. ;
Blank, Christian U. ;
O'Day, Steven J. ;
Ascierto, Paolo A. ;
Salama, April K. S. ;
Margolin, Kim A. ;
Loquai, Carmen ;
Eigentler, Thomas K. ;
Gangadhar, Tara C. ;
Carlino, Matteo S. ;
Agarwala, Sanjiv S. ;
Moschos, Stergios J. ;
Sosman, Jeffrey A. ;
Goldinger, Simone M. ;
Shapira-Frommer, Ronnie ;
Gonzalez, Rene ;
Kirkwood, John M. ;
Wolchok, Jedd D. ;
Eggermont, Alexander ;
Li, Xiaoyun Nicole ;
Zhou, Wei ;
Zernhelt, Adriane M. ;
Lis, Joy ;
Ebbinghaus, Scot ;
Kang, S. Peter ;
Daud, Adil .
LANCET ONCOLOGY, 2015, 16 (08) :908-918
[9]  
Robert C, 2015, J CLIN ONCOL, V33
[10]   Pembrolizumab versus Ipilimumab in Advanced Melanoma [J].
Robert, Caroline ;
Schachter, Jacob ;
Long, Georgina V. ;
Arance, Ana ;
Grob, Jean Jacques ;
Mortier, Laurent ;
Daud, Adil ;
Carlino, Matteo S. ;
McNeil, Catriona ;
Lotem, Michal ;
Larkin, James ;
Lorigan, Paul ;
Neyns, Bart ;
Blank, Christian U. ;
Hamid, Omid ;
Mateus, Christine ;
Shapira-Frommer, Ronnie ;
Kosh, Michele ;
Zhou, Honghong ;
Ibrahim, Nageatte ;
Ebbinghaus, Scot ;
Ribas, Antoni .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2521-2532
12